Enervit S.p.A.

Enervit S.p.A.

MMIL:ENV
4.93
EUR
-0.01
(-0.20%)
38.63MMarket Cap
Mar 17Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.94
3.01
2.94
3.05
3.09
3.44
3.55
2.91
3.64
4.3
4.8
5.48
5.8
- -
Basic EPS, GAAP
0.12
0.12
0.01
0.13
0.16
0.2
0.05
-0.11
0.2
0.23
0.22
0.23
0.24
- -
Free Cash Flow per Basic Share
0.31
-0.09
-0.11
0.33
0.02
0.05
-0.69
0.12
0.51
0.25
0.01
0.4
0.39
- -
Dividend per Share
0.03
0.05
0.05
0.03
0.08
0.08
0.11
- -
- -
0.11
0.13
0.13
0.16
- -
Book Value per Share
1.12
1.19
1.15
1.25
1.33
1.46
1.39
1.28
1.5
1.65
1.73
1.82
1.9
1.18
Tangible Book Value per Share
0.69
0.74
0.75
0.85
0.84
0.96
0.88
0.84
1.07
1.21
1.16
1.27
1.35
0.78
Basic Weighted Avg Shares
18
18
18
18
18
18
18
18
18
18
18
18
18
18
Sales/Revenue/Turnover
52
54
52
54
55
61
63
52
65
77
85
98
103
- -
Operating Margin (%)
7.21
7.71
3.82
7.66
8.87
6.8
2.8
-1.63
7.08
7.2
6.64
6.46
6.65
- -
Depreciation Expense
1
1
2
2
2
2
3
4
4
4
4
4
4
- -
Net Income, GAAP
2
2
- -
2
3
4
1
-2
4
4
4
4
4
- -
Effective Tax Rate (%)
39.87
41
41.15
36.71
34.63
13.7
36.17
- -
20.23
22.93
18.92
19.93
24.25
- -
Profit Margin (%)
4
4.06
0.35
4.38
5.1
5.77
1.36
-3.66
5.48
5.44
4.69
4.23
4.12
- -
Working Capital
9
7
6
8
7
5
5
15
17
17
16
14
18
7
LT Debt
1
1
2
4
3
2
13
21
17
13
8
5
6
5
Total Equity
20
21
20
22
24
26
25
23
27
29
31
32
34
21
Return on Invested Capital (%)
9.92
9.75
4.6
9.8
11.09
12.34
3.22
- -
7.6
8.89
8.71
1
10.52
- -
Return on Capital (%)
10.28
9.86
0.92
9.47
9.94
12.22
2.9
- -
7.99
9.36
9.61
10.66
10.98
- -
Return on Common Equity (%)
10.97
10.57
0.87
11.15
12.19
14.24
3.39
-7.99
14.36
14.86
13.31
13.04
12.85
- -

Capital Structure

EUR

•

in mil. unless spec.
Sep'15
Dec'15
Jun'16
ST Debt
1
1
2
LT Borrowings
2
2
5
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
18
18
18
Market Capitalization
54
50
39

Working Capital

EUR

•

in mil. unless spec.
Sep'15
Dec'15
Jun'16
Total Current Assets
23
20
28
Cash, Cash Equivalents & STI
5
2
3
Accounts Receivable, Net
10
10
16
Inventories
6
5
5
Total Current Liabilities
17
15
20
Payables & Accruals
- -
- -
- -
ST Debt
1
1
2
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.38%
8.31%
4.11%
Free Cash Flow
76.91%
560.84%
-2.48%
Net Income, GAAP
59.65%
-53.48%
3.16%
Sales/Revenue/Turnover
7.63%
14.95%
5.85%
Total Cash Common Dividend
- -
- -
23.08%

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
85
2024
- -
- -
98
2025
- -
- -
103

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.22
2024
- -
- -
0.23
2025
- -
- -
0.24

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.13
2024
- -
- -
0.13
2025
- -
- -
0.16

Company Description

Full Time Employees
254
Sector
Health technology
Industry
Pharmaceuticals: other
Address
Milan Italy
IPO Date
Jul 14, 2008
Business
Enervit S.p.A. is an Italy-based company engaged in the research, development, production, and commercialization of sports nutrition, dietary supplements, and functional health foods. Founded in 1954 and headquartered in Milan, Italy, the company operates within the active nutrition, health, and wellness sectors, catering to elite athletes, endurance sports practitioners, fitness enthusiasts, and health-conscious consumers. The company operates proprietary research and manufacturing facilities in Zelbio, Italy, and distributes its products across Italy, broader Europe, and international markets through specialized sports retailers, pharmacies, parapharmacies, mass merchandise chains, and direct-to-consumer e-commerce platforms. The company organizes its core offerings across specialized product categories and proprietary brand portfolios, which include: Enervit Sport, comprising carbohydrate energy gels, liquid carbo-shots, isotonic and hypotonic drink mixes, maltodextrin powders, energy bars, branched-chain amino acids (BCAAs), mineral electrolyte formulations, and post-workout muscle recovery drinks engineered for endurance disciplines such as cycling, running, and triathlon; EnerZona, encompassing nutritional solutions formulated in accordance with the Zone Diet 40-30-30 macronutrient balance, including ultra-purified Omega-3 fatty acid supplements (EnerZona Omega 3 RX), meal replacement shakes, protein biscuits, polyphenol extracts, and low-glycemic wellness snacks; Enervit Protein and Gymline, featuring whey protein isolates and concentrates, plant-based proteins, creatine monohydrate, glutamine powders, pre-workout stimulants, and high-protein, low-sugar snack bars tailored for bodybuilding, gym training, and lean muscle maintenance; and medical and general wellness supplements, including multivitamins, mineral complexes, and joint and immune support formulations. In recent developments, Enervit S.p.A. has executed strategic initiatives focused on premium product innovation, international market expansion, and prestigious athletic partnerships. The company introduced its high-performance Enervit C2:1PRO line, a specialized endurance nutrition range featuring a 2:1 maltodextrin-to-fructose carbohydrate matrix designed to maximize energy uptake during high-intensity endurance competitions. Enervit has also expanded and renewed key technical partnerships with elite sporting entities, serving as the official nutrition partner for UCI WorldTour cycling teams such as UAE Team Emirates and Lidl-Trek, the Italian Cycling Federation, the Italian Triathlon Federation, and premier mass-participation endurance events including the Vasaloppet cross-country ski race and European Ironman competitions. Operationally, the company has continued to modernize and expand production capacity at its Zelbio manufacturing hub, while scaling its direct-to-consumer digital channels and broadening distribution networks across key European export markets including Spain, Germany, Austria, and the Nordic region.